Lonza will combine its custom manufacturing and bioscience business units into a pharma market segments group. The microbial control and life science ingredients businesses will be regrouped into a specialty ingredients market segments group. The company has also restructured its renamed Executive Committee. The committee will and will consist of five members: Richard Ridinger - CEO, Toralf Haag - CFO, Marc Funk - CLO, Stephan Kutzer - COO and Beat In-Albon - COO.
In-pharma Technologist
Tuesday, 5 February 2013
Lonza starts to restructure
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment